Literature DB >> 10482479

Epidemiological features and visual prognosis of Behçet's disease.

K Ando1, Y Fujino, K Hijikata, Y Izawa, K Masuda.   

Abstract

PURPOSE: Retrospective evaluation of epidemiological features and visual prognosis of patients with Behçet's disease (BD) who visited the University of Tokyo Hospital between 1974 and 1993. OBSERVATIONS: During the survey period, more than 100 new patients with BD visited the uveitis clinic in each 5-year period. The number of new patients decreased in the most recent 5-year period from 1989 to 1993. Although BD has always been more prevalent in men, the percentage of women has increased to 24.7% (19/77) in the most recent 5-year survey period. The percentage of patients who initially manifested ocular symptoms in their third or fourth decade was more than 70%. The proportion of the incomplete type of BD gradually had increased to 62.3% (48/77) by 1993. Among the extraocular major symptoms, oral aphtha and skin lesions have been frequent and genital ulcer has become less frequent in the last 20 years. The patients whose visual acuity was better than 0.4 at the first visit in the 1984-1993 period had a significantly better visual prognosis than the patients in the previous 10-year period. The main drug therapy consisted of colchicine and cyclophosphamide in the earlier 10-year period, and of colchicine and ciclosporin in the later 10-year period.
CONCLUSIONS: Behçet's disease is still one of the most frequently encountered types of endogenous uveitis. There have been some changes in the epidemiological features of the patients with BD over the past 20 years. The introduction of ciclosporin in 1985 is probably responsible for the improvement of the visual prognosis in BD patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482479     DOI: 10.1016/s0021-5155(99)00029-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  13 in total

1.  [Epidemiology of ocular involvement in Adamantiades-Behçets disease].

Authors:  C E Kneifel; A-K Köhler; A Altenburg; C C Zouboulis; L Krause
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

2.  Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany.

Authors:  Lothar Krause; Anne-Katrin Köhler; Andreas Altenburg; Nestor Papoutsis; Christos C Zouboulis; Uwe Pleyer; Andrea Stroux; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-04       Impact factor: 3.117

3.  [Behçet's disease].

Authors:  I Kötter; T Xenitidis; G Fierlbeck; S Schanz; A Melms; M Horger; U Ernemann; C Deuter
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

Review 4.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

5.  [Extraocular manifestations of Behcet's disease].

Authors:  I Kötter; T Xenitidis; G Fierlbeck; S Schanz; A Melms; M Horger; U Ernemann; C Deuter
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

6.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Topographic optic disc analysis by Heidelberg retinal tomography in ocular Behcet's disease.

Authors:  Nilufer Berker; Ufuk Elgin; Pinar Ozdal; Aygen Batman; Emel Soykan; Seyhan S Ozkan
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

9.  Clinical characteristics of Behçet's disease in China.

Authors:  Liao-Yuan Wang; Dong-Bao Zhao; Jun Gu; Sheng-Ming Dai
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

10.  Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute.

Authors:  Leila I Kump; Kristy L Moeller; George F Reed; Shree K Kurup; Robert B Nussenblatt; Grace A Levy-Clarke
Journal:  Can J Ophthalmol       Date:  2008-08       Impact factor: 1.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.